CG Oncology bladder cancer trial to deliver key results nearly a year early

CG Oncology (NASDAQ: CGON) announced that topline Phase 3 data from the PIVOT-006 study in intermediate-risk non-muscle invasive bladder cancer (IR NMIBC) is now expected in 1H 2026, roughly one year earlier than previously planned due to expedited enrollment. The randomized, open-label registrational trial compares adjuvant intravesical cretostimogene grenadenorepvec versus surveillance after tumor removal in >360 patients across 90+ sites. PIVOT-006 is described as the first Phase 3 randomized trial in this IR NMIBC population and includes the broadest range of patient types per AUA/SUO guidelines.

https://www.stocktitan.net/news/CGON/cg-oncology-provides-updated-timeline-for-pivot-006-phase-3-topline-61ne281x6kb1.html